Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 4071-4080

  Riemenschneider, Jenny ^a,b   Garrison, Aura ^a   Geisbert, Joan ^a   Jahrling, Peter ^a   Hevey, Michael ^a   Negley, Diane ^a   Schmaljohn, Alan ^a   Lee, John ^a   Hart, Mary Kate ^a   Vanderzanden, Lorna ^a   Custer, David ^a   Bray, Mike ^a,c   Ruff, Albert ^a,d   Ivins, Bruce ^a   Bassett, Anthony ^a   Rossi, Cynthia ^a   Schmaljohn, Connie ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d LEE UNIVERSITY   (United States)

Author keywords

Bacillus anthracis; DNA vaccines; EBOV and MARV; VEEV

Indexed keywords

ANTHRAX EBOLA MARBURG ENCEPHALITIS VACCINE; ANTHRAX VACCINE; DNA VACCINE; EBOLA VACCINE; ENCEPHALITIS VACCINE; MARBURG VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EBOLA VIRUS; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; MARBURG VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS ENCEPHALITIS; VIRUS HEMORRHAGIC FEVER;

EID: 10744230259     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00362-1     Document Type: Article

References (52)

1. Roy M.J., Wu M.S., Barr L.J.et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine. 19(7-8):2000;764-778.
2. Ulmer J.B. An update on the state of the art of DNA vaccines. Curr. Opin. Drug Discovery Dev. 4(2):2001;192-197.
3. Doolan D.L., Hedstrom R.C., Gardner M.J.et al. DNA vaccination as an approach to malaria control: current status and strategies. Curr. Top Microbiol Immunol. 226:1998;37-56.
4. Morris S., Kelley C., Howard A., Li Z., Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine. 18(20):2000;2155-2163.
5. Musacchio A., Rodriguez E.G., Herrera A.M., Quintana D., Muzio V. Multivalent DNA-based immunization against hepatitis B virus with plasmids encoding surface and core antigens. Biochem Biophys Res Commun. 282(2):2001;442-446.
6. Mikesell P. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun. 39(1):1983;371-376.
7. Milne J.C., Blanke S.R., Hanna P.C., Collier R.J. Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol Microbiol. 15(4):1995;661-666.
8. Welkos S., Little S., Friedlander A., Fritz D., Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology. 147(Pt 6):2001;1677-1685.
9. Ivins B.E., Welkos S.L. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect Immun. 54(2):1986;537-542.
10. Ezzell J.W., Welkos S.L. The capsule of bacillus anthracis, a review. J Appl Microbiol. 87(2):1999;250.
11. Alibek, K. Biohazard, Dell Publishing, 2000.
12. Olson K.B. Aum Shinrikyo: once and future threat? Emerg Infect Dis. 5:1999;513-516.
13. Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, Peters CJ. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields virology, vol. 1. Philadelphia (PA): Lippincott Williams & Wilkins; 2001. p. 1279-1304.
14. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 8(5):2002;503-507.
15. Wilson J.A., Bosio C.M., Hart M.K. Ebola virus: the search for vaccines and treatments. Cell Mol Life Sci. 58(12-13):2001;1826-1841.
16. Griffin D. Alphaviruses. In: Knipe DM, Howley PM, editors. Fields virology, vol. 1. New York: Lippincott Williams & Wilkins; 2001. p. 917-62.
17. Berge T.O., Banks L.S., Tiggert W.D. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells. Am J Trop Med Hyg. 73:1961;209-218.
18. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 14(4):1996;337-343.
19. Jahrling P.B., Stephenson E.H. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J Clin Microbiol. 19(3):1984;429-431.
20. Schmaljohn C., VanderZanden L., Bray M.et al. Naked DNA vaccines expressing the prM and E genes of Russian Spring Summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J. Virol. 71:1997;9563-9569.
21. Iacono-Connors L.C., Schmaljohn C.S., Dalrymple J.M. Expression of the Bacillus anthracis protective antigen gene by baculovirus and vaccinia virus recombinants. Infect Immun. 58(2):1990;366-372.
22. Vanderzanden L., Bray M., Fuller D.et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 246(1):1998;134-144.
23. Hevey M., Negley D., VanderZanden L.et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine. 2892:2001;1-8.
24. Hodgson L.A., Ludwig G.V., Smith J.F. Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine. 17(9-10):1999;1151-1160.
25. Farchaus J.W., Ribot W.J., Jendrek S., Little S.F. Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl Environ Microbiol. 64(3):1998;982-991.
26. Pitt M.L., Little S.F., Ivins B.E.et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine. 19(32):2001;4768-4773.
27. Little S.F., Ivins B.E., Fellows P.F., Friedlander A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun. 65(12):1997;5171-5175.
28. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever [published erratum appears in J Infect Dis 1998;178(5):1553]. J Infect Dis 1998;178(3):651-61.
29. Hevey M., Negley D., Geisbert J., Jahrling P., Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 239:1997;206-216.
30. Hevey M., Negley D., Pushko P., Smith J., Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 251(1):1998;28-37.
31. Hart M.K., Pratt W., Panelo F., Tammariello R., Dertzbaugh M. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Vaccine. 15(4):1997;363-369.
32. Smith D.H., Johnson B.K., Isaacson M.et al. Marburg-virus disease in Kenya. Lancet. 1(8276):1982;816-820.
33. Johnson E.D., Johnson B.K., Silverstein D.et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch Virol. 11(Suppl):1996;101-114.
34. Connolly B.M., Steele K.E., Davis K.J.et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis. 179(Suppl 1):1999;S203-217.
35. Liljestrom P., Garoff H. Internally located cleavable signal sequences direct the formation of Semliki Forest virus membrane proteins from a polyprotein precursor. J Virol. 65(1):1991;147-154.
36. Wahlberg J.M., Boere W.A., Garoff H.et al. The heterodimeric association between the membrane proteins of Semliki Forest virus changes its sensitivity to low pH during virus maturation. J Virol. 63(12):1989;4991-4997.
37. Mathews J.H., Roehrig J.T. Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. J Immunol. 129(6):1982;2763-2767.
38. Schmaljohn A.L., Johnson E.D., Dalrymple J.M., Cole G.A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature. 297(5861):1982;70-72.
39. Mathews J.H., Roehrig J.T., Trent D.W. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol. 55(3):1985;594-600.
40. Pertmer T.M., Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol. 70(9):1996;6119-6125.
41. Hooper J.W., Custer D.M., Schmaljohn C.S., Schmaljohn A.L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology. 266(2):2000;329-339.
42. Schmaljohn C., Custer D., VanderZanden L., Spik K., Rossi C., Bray M. Evaluation of tick-borne encephalitis DNA vaccines in monkeys. Virology. 263(1):1999;166-174.
43. Hooper J.W., Custer D.M., Thompson E., Schmaljohn C.S. DNA vaccination with the hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J Virol. 75(18):2001;8469-8477.
44. Babiuk S., Baca-Estrada M., Babiuk L.A., Ewen C., Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release. 66(2-3):2000;199-214.
45. Mikszta J.A., Alarcon J.B., Brittingham J.M., Sutter D.E., Pettis R.J., Harvey N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med. 8(4):2002;415-419.
46. Ivins B.E., Fellows P.F., Nelson G.O. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine. 12(10):1994;872-874.
47. Ivins B., Fellows P., Pitt L.et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine. 13(18):1995;1779- 1784.
48. Arrington J., Braun R.P., Dong L. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol. 76(9):2002;4536-4546.
49. Xu L., Sanchez A., Yang Z.et al. Immunization for Ebola virus infection. Nat Med. 4(1):1998;37-42.
50. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 408(6812):2000;605-609.
51. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 77(1):2003;799-803.
52. Mellquist-Riemenschneider J, Garrison A, Geisbert J, et al. Evaluation of baculovirus-derived Ebola virus GP in a DNA prime-protein boost vaccine regimen. Virus Res 2003;92:187-93.